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Tablets dosage formAbstract A simple, rapid and selective high performance thin layer chromatography (HPTLC)
method was developed for the simultaneous determination of cinnarizine (CNZ) and dimenhydri-
nate (DMH) in pure form and in their combined dosage form. Reviewing the literature revealed that
there are no reports for the use of TLC for the assay of this mixture. Effective separation was
achieved using Fluka HPTLC aluminum sheets of silica gel 60 F254 using chloroform–n-hexane–
methanol (8.5:0.8:0.7, by volume) as mobile phase, followed by densitometric measurement of
CNZ and DMH spots at 254 and 279 nm, respectively. The reliability and analytical performance
of the proposed HPTLC method were statistically validated with respect to linearity, ranges, preci-
sion, accuracy, selectivity, robustness and detection and quantiﬁcation limits. Calibration curves
were linear in the ranges of 50–400 and 50–500 ng/spot for CNZ and DMH, respectively with cor-
relation coefﬁcients >0.9998. The limits of detection were 8.1 and 8.0 ng/spot for CNZ and DMH
respectively. The validated HPTLC method was applied to the simultaneous analysis of CNZ and
DMH in laboratory-prepared tablets. Both analytes were successfully quantiﬁed with good recovery
values, and no interference was encountered from the inactive ingredients.
ª 2014 Production and hosting by Elsevier B.V. on behalf of University of Bahrain.1. Introduction
Cinnarizine (CNZ) (Fig. 1), chemically known as
(E)-1-(Diphenylmethyl)-4-(3-phenylprop-2-enyl)piperazine, is
a piperazine derivative with antihistamine, sedative and cal-cium-channel blocking activity. It is used for the symptomatic
treatment of nausea and vertigo caused by Me´nie`re’s disease
and other vestibular disorders and for the prevention
and treatment of motion sickness. It is also used in the
management of various peripheral and cerebral vascular disor-
ders (Sweetman, 2009). The British Pharmacopoeia (BP)
describes a non-aqueous titration procedure for the assay of
CNZ (The British Pharmacopoeia, 2010). Alternatively, sev-
eral methods have been described in the literature for the deter-
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Figure 1 Chemical structures of cinnarizine (CNZ) and dimen-
hydrinate (DMH).
16 D.S. El-Kafrawy, T.S. Belalmination of CNZ in its pharmaceutical dosage forms or in bio-
logical samples. Examples of these methods are various spec-
trophotometric and/or chemometric spectrophotometric
methods (El-Gindy et al., 2004; Metwally et al., 2005; Gazy
et al., 2006; El-Bardicy et al., 2008; Abdelrahman, 2013), syn-
chronous ﬂuorescence spectroscopy (Walash et al., 2008),
chemiluminescence using ﬂow-injection analysis (Townshend
et al., 2003), voltammetry (El-Sayed et al., 2008; Hegde
et al., 2009), potentiometric membrane sensors (Hassan
et al., 1996), HPLC with UV detection (El-Gindy et al.,
2004; Metwally et al., 2005; Heda et al., 2010; Navaneethan
et al., 2013), HPLC with ﬂuorescence detection (Angelov and
Christova-Bagdassarian, 2003; Nowacka-Krukowska et al.,
2007) and capillary electrophoresis (Abdelal et al., 2008).
Few articles reported the HPTLC determination of pharma-
ceutical mixtures containing CNZ with piracetam (Metwally
et al., 2005) and domperidone (Argekar and Powar, 1999;
Bagade et al., 2005; Vinodhini et al., 2005).
Dimenhydrinate (DMH) (Fig. 1) is the diphenhydramine
salt of 8-chlorotheophylline. It is chemically known as 8-
chloro-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione com-
pound with 2-(diphenylmethoxy)-N,N-dimethylethanamine
(1:1) (Moffat et al., 2004). DMH is an antihistamine with
antimuscarinic and signiﬁcant sedative effects. It is mainly
used as an antiemetic in the prevention and treatment of
motion sickness. It is also used for the symptomatic treatment
of nausea and vertigo caused by Me´nie`re’s disease and other
vestibular disturbances (Sweetman, 2009). The DMH mono-
graph in the BP describes titration procedures for the assay
of the bulk powder and tablets (The British Pharmacopoeia,
2010). On the other hand, the United States Pharmacopeia
(USP) suggests a titration procedure for the bulk form, while
HPLC is recommended for the assay of all DMH dosage forms
(The United States Pharmacopeia, 2011). The quantiﬁcation of
DMH in various drug formulations and/or biological samples
was addressed in some reports. Analytical methodology in
these reports involved the use of spectrophotometry (Kar
and Aniuha, 1981; Mitic et al., 2012), UV spectroscopic mult-
isensor with the aid of partial least squares (PLS) regression
(Can˜ada et al., 1999), adsorptive stripping voltammetry(Shubietah et al., 1999), capillary electrophoresis (Ong et al.,
1991), liquid chromatography-tandem mass spectrometry
(LC-MS-MS) (Tavares et al., 2007), HPLC with ﬂuorescence
detection (O¨zkan et al., 2013) and HPLC with UV detection
(Barbas et al., 2000; Do¨ge and Eger, 2007). Only a single pub-
lished paper reported the HPTLC determination of DMH in
tablets (DiGregorio et al., 2000).
CNZ (20 mg) and DMH (40 mg) are co-formulated in a
ﬁxed-dose combination tablets for treatment of vestibular ver-
tigo of central and/or peripheral origin. The efﬁcacy of the
ﬁxed combination exceeded that of each of the equally dosed
active substances given as monotherapy (Hahn et al., 2011;
Arlevert webpage). Few reports can be found in the scientiﬁc
literature for the simultaneous determination of CNZ and
DMH. These reports presented HPLC with UV detection
(Patel et al., 2012) and spectrophotometric methods (Shah
and Patel, 2012a,b). To the best of our knowledge, no attempts
have yet been made to assay this drug combination by any
TLC method. HPTLC is becoming a routine analytical tech-
nique due to its advantages of low operating cost, high sample
throughput, and minimum sample clean up. The major advan-
tage of HPTLC is that several samples can be run simulta-
neously using a small quantity of mobile phase unlike
HPLC, thus lowering analysis time and cost per analysis.
The aim of this work is the development of a simple, rapid
and reliable HPTLC procedure for the simultaneous estima-
tion of CNZ and DMH in pure form and in tablets.
2. Experimental
2.1. Instrumentation and chromatographic conditions
The samples were spotted in the form of bands with a Cammag
microliter syringe under nitrogen stream using a Cammag Lin-
omat IV sample applicator (Switzerland). Precoated TLC silica
gel aluminum plates 60 F254 (20 · 20 cm, 200 lm thickness,
Fluka, Switzerland) were used. Development was performed
in a Cammag twin trough glass chamber (20 · 20 cm) satu-
rated with the mobile phase. The mobile phase (20 mL) was
chloroform:n-hexane:methanol (8.5:0.8:0.7, v/v/v). The opti-
mized chamber saturation time for mobile phase was 30 min
at room temperature (25 ± 2 C). Densitometric scanning
was performed on Cammag TLC scanner III operated by
CATS software (V 3.15 CAMAG). The source of radiation uti-
lized was deuterium lamp emitting a continuous UV spectrum
between 190 and 400 nm. The obtained spots were scanned at
three wavelengths 220, 254 and 279 nm.
2.2. Materials
Pharmaceutical grades of CNZ and DMH were kindly sup-
plied by Amriya Pharmaceutical Industries, Alexandria,
Egypt. Analytical grade of all solvents was used including
methanol (Fine-Chem Limited, Mumbai, India), n-hexane
(Carlo-Erba Reagents, SDS, France) and chloroform (BDH
Chemicals Ltd, Poole, England). The formulation assayed in
the study was laboratory-prepared tablets each containing
20 mg CNZ and 40 mg DMH. The prepared tablets contained
maize starch, microcrystalline cellulose (Avicel), magnesium
stearate, hydroxypropylmethylcellulose (HPMC) and colloidal
Figure 2 HPTLC chromatograms of a mixture of 200 ng/spot
CNZ and 400 ng/spot DMH at 220 nm (A), 254 nm (B) and
279 nm (C). The peaks correspond to diphenhydramine (1), 8-
chlorotheophylline (2) and cinnarizine (3).
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tively as tablet ﬁllers. These tablet ﬁllers were obtained from
Pharco Pharmaceuticals Co., Alexandria, Egypt.
2.3. General procedure
CNZ stock solution (500 lg/mL) and DMH stock solution
(500 lg/mL) were prepared in methanol. The working solu-
tions were prepared by dilution of the stock solutions with
methanol to reach the concentration ranges 10–80 and 10–
100 lg/mL for CNZ and DMH respectively. From each work-
ing standard solution, 5-lL portions were spotted as bands on
HPTLC plate to obtain ﬁnal concentrations of 50–400 and
50–500 ng/spot for CNZ and DMH, respectively. Triplicate
applications were made for each solution. The plate was then
developed using the previously described mobile phase. The
peak areas of CNZ and DMH at 254 and 279 nm, respectively
were plotted against the corresponding concentrations to
obtain the calibration graph for each compound.
2.4. Assay of laboratory-prepared tablets
A total of 10 tablets were weighed and ﬁnely powdered. To an
accurately weighed quantity of the powder equivalent to 25 mg
CNZ and 50 mg DMH, 25 mL methanol were added, stirred
for 20 min then ﬁltered into a 50-mL volumetric ﬂask. The res-
idue was washed with two 10 mL portions of methanol and
washings were added to the ﬁltrate and diluted to volume with
the same solvent. Aliquots of the tablet solution were diluted
with methanol to obtain ﬁnal concentrations within the previ-
ously mentioned concentration ranges. From each working
sample solution, 5-lL portions were spotted as bands on
HPTLC plate to obtain ﬁnal concentrations within the speci-
ﬁed ranges (50–400 and 50–500 ng/spot for CNZ and DMH,
respectively), and then chromatographed using the conditions
mentioned earlier. Recovery values were calculated from sim-
ilarly treated external standard solutions. For standard addi-
tion assay, sample solutions were spiked with aliquots of
standard solutions of both compounds to obtain total concen-
trations within the previously speciﬁed ranges then treated as
under General procedure. Recovered concentrations were cal-
culated by comparing the analyte response with the increment
response attained after addition of the standard.
3. Results and discussion
3.1. Optimization of HPTLC densitometric method
The experimental conditions, such as mobile phase composi-
tion and wavelength of detection were optimized to achieve
the best separation between CNZ and DMH, together with
the separation of the components of DMH (diphenhydramine
and 8-chlorotheophylline). Various solvent systems were care-
fully evaluated to reach an optimum resolution of the mixture
components. Initially, methylene chloride and methanol or
ethanol in different ratios were tried but insufﬁcient separation
between 8-chlorotheophylline and CNZ occurred even upon
the addition of minute amounts of acetic acid or ammonia
to the mobile phase. In these previous trials, diphenhydramine
was easily separated however 8-chlorotheophylline and cinnar-izine were not adequately resolved. Retardation factors (Rf)
were about 0.15, 0.74 and 0.78 for diphenhydramine, 8-chloro-
theophylline and cinnarizine, respectively. Replacing methy-
lene chloride by chloroform in different ratios with methanol
resulted in a slight improvement that happened only in a ratio
of chloroform and methanol (9:1, v/v). This improvement was
demonstrated by the slightly better resolution between 8-
chlorotheophylline and cinnarizine (Rf = 0.69 and 0.76, respec-
tively). Again, addition of minute amounts of acetic acid or
ammonia to the aforementioned mobile phase did not improve
the separation. On the other hand, addition of n-hexane or
toluene to the same mobile phase produced substantial
improvement in both separation and peak characteristics.
The optimized solvent system consisting of chloroform:n-
hexane:methanol (8.5:0.8:0.7, v/v/v) showed an acceptable
TLC resolution and gave compact spots together with sharp
and well deﬁned symmetrical peaks for all separated
components.
Table 1 Analytical parameters for the determination of
CNZ–DMH mixture using the proposed HPTLC method.
Parameter CNZ DMH
Wavelength (nm) 254 279
Concentration range (ng/spot) 50–400 50–500
Intercept (a) 28.64 12.45
Sa
a 33.77 30.04
Slope (b) 13.72 12.39
Sb
b 0.14 0.10
RSD% of the slope 1.02 0.81
Correlation coeﬃcient (r) 0.99985 0.99991
Sy/x
c 39.32 38.25
Fd 9981 15729
Signiﬁcance F 2.21 · 106 1.12 · 106
LODe(ng/spot) 8.12 8.00
LOQf(ng/spot) 24.61 24.25
a Standard deviation of the intercept.
b Standard deviation of the slope.
c Standard deviation of residuals.
d Variance ratio, equals the mean of squares due to regression
divided by the mean of squares about regression (due to residuals).
e Limit of detection.
f Limit of quantiﬁcation.
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order to achieve the highest sensitivity for quantiﬁcation of
both drugs. CNZ exhibits an absorption band with maximum
at 254 nm which was chosen for its measurement. DMH is
resolved into two components: the diphenhydramine compo-
nent is a weak UV absorbing compound with measurable
absorbance only in the short UV region (below 230 nm); con-
sequently, 220 nm was found suitable to detect its peak. On the
other hand, the 8-chlorotheophylline shows an absorption
spectrum with prominent maximum at 279 nm which was
selected for its measurement. Fig. 2 shows typical HPTLC
chromatograms for the separation of standard mixture of
CNZ and DMH using the optimized conditions. As illustrated
in Fig. 2, peaks of diphenhydramine, 8-chlorotheophylline and
cinnarizine appear at retardation factor (Rf) values of 0.10,Table 2 Precision and accuracy for the determination of CNZ and
Analyte Nominal value (ng/spot) Found
Within-day analysis
CNZ 100 99.91
200 199.65
300 301.02
DMH 200 200.21
300 298.58
400 399.65
Between-day analysis
CNZ 100 99.63
200 200.74
300 301.43
DMH 200 201.32
300 301.68
400 398.52
a Mean ± standard deviation for three determinations.
b % relative standard deviation.
c % relative error.0.49 and 0.62, respectively. It is reported that a resolution
value of 1 implies almost complete separation between two
successive peaks, and a resolution of 1.25 is sufﬁcient for quan-
titative measurements (Spangenberg et al., 2011). Resolution
values were found to be 4.59 between diphenhydramine and
8-chlorotheophylline peaks, and 1.37 between 8-chlorotheoph-
ylline and cinnarizine peaks.
Taking into consideration the range of concentrations
applied and number of tracks, the optimum band width was
6 mm and the best interspaces between bands were 5 mm.
The spots appeared more compact and peak shapes were more
symmetrical when the HPTLC plates were pretreated with
methanol and activated at 80 C for 10 min. Well deﬁned spot
for each compound was obtained when the developing cham-
ber was saturated for 30 min at room temperature.
3.2. Validation of the proposed method
The proposed method was validated according to the Interna-
tional Conference on Harmonization (ICH) guidelines on
validation of analytical procedures (ICH, 2005).
3.2.1. Linearity and concentration ranges
The linearity of the proposed HPTLC procedure was evalu-
ated by analyzing a series of different concentrations for each
of the two analytes. The linear regression equations were gen-
erated by least squares treatment of the calibration data. In
case of DMH, peaks of the 8-chlorotheophylline component
at 279 nm provide higher area values and more reliable mea-
surement than those of diphenhydramine at 220 nm; therefore
quantiﬁcation of DMH was based on measurement of 8-chlo-
rotheophylline peak areas at 279 nm. Under the optimized
conditions described above, the measured peak areas at 254
and 279 nm were found to be proportional to concentrations
of CNZ and DMH, respectively. Table 1 presents the perfor-
mance data and statistical parameters including linear regres-
sion equations, concentration ranges, correlation coefﬁcients,
standard deviations of the intercept (Sa), slope (Sb) and stan-
dard deviations of residuals (Sy/x). Regression analysis showsDMH in bulk form using the proposed HPTLC method.
± SDa (ng/spot) RSDb (%) Er
c (%)
± 0.37 0.37 0.09
± 0.95 0.48 0.17
± 1.03 0.34 0.34
± 0.37 0.19 0.11
± 1.24 0.42 0.47
± 0.35 0.09 0.09
± 0.75 0.75 0.37
± 1.20 0.60 0.37
± 2.01 0.67 0.48
± 1.32 0.66 0.66
± 1.63 0.54 0.56
± 1.29 0.32 0.37
Figure 3 Overlay spectra of standard and sample 200 ng/spot
CNZ (A) and 400 ng/spot DMH (B).
Table 3 Determination of CNZ–DMH laboratory-prepared mixtures using the proposed HPTLC method.
Nominal value (ng/spot) Found ± SDa (ng/spot) RSDb (%) Er
c (%)
CNZ DMH CNZ DMH CNZ DMH CNZ DMH
100 400 100.10 ± 0.65 400.19 ± 1.04 0.65 0.26 0.10 0.05
100 300 99.72 ± 0.40 299.91 ± 1.62 0.40 0.54 0.28 0.03
100 200 99.85 ± 0.11 199.65 ± 0.67 0.11 0.34 0.15 0.17
300 300 299.41 ± 1.69 298.10 ± 0.37 0.56 0.12 0.20 0.63
200 100 199.45 ± 0.66 99.48 ± 0.32 0.33 0.32 0.27 0.52
a Mean ± standard deviation for ﬁve determinations.
b % relative standard deviation.
c % relative error.
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values (>0.9998). In addition, deviation around the slope
can be further evaluated by calculation of the RSD% of the
slope (Sb%) which were found to be less than 1.1%. In addi-
tion to the previous parameters, linearity can be further guar-
anteed by the analysis of variance (ANOVA) test (Miller and
Miller, 2000). The most important statistic in this test is the
F-value which is the ratio of the mean of squares due to regres-
sion divided by the mean of squares due to residuals. High F
values reveal an increase in the mean of squares due to regres-
sion and a decrease in the mean of squares due to residuals.
The greater the mean of squares due to regression, the steeper
is the regression line. The smaller the mean of squares due to
residuals, the less is the scatter of experimental points around
the regression line. Consequently, regression lines with high F
values (low signiﬁcance F) are much better than those with
lower ones. Good regression lines show high values for both
r and F statistical parameters.
3.2.2. Detection and quantiﬁcation limits
Limit of detection (LOD) was deﬁned as 3.3 Sa/b and limit of
quantiﬁcation (LOQ) was computed as 10 Sa/b, where Sa is the
standard deviation of the intercept and b is the slope of the cal-
ibration curve. The sensitivity of the proposed method can be
conﬁrmed by the low LOD and LOQ values obtained
(Table 1).
3.2.3. Precision and accuracy
The within-day repeatability of the proposed method was
assessed through the analysis of three concentration levels
for each drug prepared in triplicates. Correspondingly, the
between-day precision was studied on the same levels over
three consecutive days. Table 2 shows the values of percentage
relative standard deviation (RSD%) which did not exceed 1%
for both drugs indicating the high level of precision of the pro-
posed method. The adequate recovered concentrations in addi-
tion to the low values of percentage relative error (Er%)
gathered in Table 2 also conﬁrm the accuracy of the developed
method.
3.2.4. Selectivity
Method selectivity was examined by preparing several labora-
tory-prepared mixtures of the two compounds at various con-
centrations within the linearity ranges mentioned in Table 1.
These mixtures were of different ratios both above and
below the normal ratio expected in the dosage form (CNZ–
DMH 1:2). The laboratory-prepared mixtures were analyzedaccording to the previously described procedure. The analysis
results including percentage relative standard deviation
(RSD%) and the percentage relative error (Er%) values shown
in Table 3 were satisfactory thus validating the selectivity, pre-
cision and accuracy of the developed method and demonstrat-
ing its capability to resolve and quantify the analytes in
different ratios.
3.2.5. Robustness
The robustness of an analytical procedure is a measure of its
capability to remain unaffected by small but deliberate varia-
tions in method parameters and provides an indication of its
reliability during normal usage (ICH, 2005). Robustness was
examined by making small changes in the mobile phase com-
position and volume. The ratios of the two minor components
of the mobile phase (n-hexane and methanol) were slightly
Figure 4 HPTLC chromatograms of the inactive ingredients
extract at 254 nm (A) and 279 nm (B).
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tested (±5 mL). It was found that variation in the studied
parameters had no signiﬁcant inﬂuence on the separation
and quantiﬁcation of CNZ and DMH using the proposed
method. In these experiments, the drugs were effectively sepa-
rated with almost unchanged retardation factors (Rf) (Table 4).
Moreover, values of RSD% of the peak areas of both drugsTable 4 Robustness of the proposed HPTLC method for determin
Parameters CNZ
RSD% of p
Mobile phase composition chloroform:hexane:methanol
(8.5:0.6:0.9)
(8.5:0.8:0.7)
(8.5:1.0:0.5)
0.172
Mobile phase volume (15, 20 and 25 mL) 0.224
Average of three determinations of 100 ng/spot for CNZ and DMH.
Table 5 Application of the proposed HPTLC procedure to the ana
the external standard method.
Nominal value (ng/spot) Found ± SDa (ng/spot)
CNZ DMH CNZ DMH
50 100 49.93 ± 0.24 99.62
100 200 100.50 ± 0.52 200.75
200 400 200.08 ± 0.14 400.14
a Mean ± standard deviation for ﬁve determinations. Similarly treate
trations using the equation:
Found concentration in sample
Concentration of standard
¼ Area of sample
Area of standard
b % relative standard deviation.
c % relative error.under the investigated changes did not exceed 0.4% (Table 4).
The low values of RSD% of peak areas along with obviously
unaffected Rf values indicated the robustness of the developed
method.
3.2.6. Stability of solutions
The stability of working solutions in the diluting solvent
(methanol) was examined and no chromatographic changes
were observed within 24 h at room temperature. Chromato-
graphic parameters including Rf values and peak areas of the
drugs remained almost unchanged and no signiﬁcant degrada-
tion was observed during this period. Also, the stock solutions
prepared in methanol were stable for at least two weeks when
stored refrigerated at 4 C.
3.3. Analysis of pharmaceutical dosage form
Due to the unavailability of the commercial tablets in the local
market, laboratory-made tablets were prepared and analyzed
by the proposed HPTLC method. The active ingredients
(CNZ and DMH) eluted at their speciﬁc Rf values. No interfer-
ing peaks were observed from any of the inactive ingredients.
Peak purity was veriﬁed by comparing the absorption spectra
of each drug obtained from tablets analysis with those of the
drug standard solution. The spectra were found identical and
superimposable as shown in Fig. 3. Furthermore, a methanol
extract of the inactive ingredients used in the preparation of
tablets (maize starch, microcrystalline cellulose, magnesium
stearate, HPMC and colloidal silica) was chromatographed
using the developed procedure then scanned at the workingation of CNZ and DMH.
DMH
eak area Rf ± SD RSD% of peak area Rf ± SD
0.63 ± 0.012 0.362 0.48 ± 0.021
0.63 ± 0.015 0.323 0.48 ± 0.015
lysis of CNZ–DMH mixture in laboratory prepared tablets using
RSDb (%) Er
c (%)
CNZ DMH CNZ DMH
± 0.42 0.48 0.42 0.14 0.38
± 0.40 0.52 0.20 0.50 0.38
± 1.48 0.07 0.37 0.04 0.04
d external standards were used to calculate sample (found) concen-
Table 6 Application of the proposed HPTLC procedure to the analysis of CNZ–DMH mixture in laboratory prepared tablets using
the standard addition method.
Standard added (ng/spot) Theoretical content (ng/spot) Found content (ng/spot) Found ± SDa (ng/spot) RSDb (%) Er
c (%)
CNZ
0 100 100.08
50 150 150.06 49.98 ± 0.11 0.22 0.05
100 200 200.02 99.94 ± 0.02 0.02 0.06
200 300 300.12 200.04 ± 0.73 0.36 0.02
DMH
0 100 100.12
50 150 150.13 50.01 ± 0.18 0.35 0.03
100 200 199.84 99.72 ± 0.24 0.24 0.28
200 300 300.22 200.07 ± 0.49 0.24 0.04
a Mean ± standard deviation for ﬁve determinations.
b % relative standard deviation.
c % relative error.
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extract illustrated in Fig. 4 reveal the absence of any interfering
peaks which can be considered further evidence for selectivity
of the proposed method for the assay of CNZ and DMH.
Recovered concentrations were calculated using both external
standard and standard addition methods (Tables 5 and 6). For
the external standard analysis, the contents of both drugs in
tablets were determined by analysis of three independently pre-
pared solutions each repeated 5 times, and recovered (found)
concentrations were calculated using similarly treated standard
solutions (Table 5). For the standard addition analysis, tablet
solutions were spiked with different portions of standard solu-
tions of the two drugs at three levels: 50%, 100% and 200% of
the nominal concentration; and the assay of each solution was
repeated 5 times (Table 6). The assay results revealed satisfac-
tory accuracy and precision as indicated from the recovered
(found) concentrations, SD, RSD% and Er% values. It is evi-
dent from these results that the proposed method is applicable
to the assay of this ﬁxed dose combination with satisfactory
level of selectivity, accuracy and precision.4. Conclusion
This study described a simple, selective and reliable HPTLC
procedure for the simultaneous determination of cinnarizine
and dimenhydrinate. Very few reports can be found for the
analysis of this recently introduced pharmaceutical mixture.
Reviewing the literature exposed that there were no reports
for the application of a TLC-based method for the assay of
this mixture. Obviously, the described HPTLC method offers
selectivity advantage over the previously published spectro-
photometric non-separation methods (Shah and Patel,
2012a,b). Moreover, the proposed method does not require
elaborate treatment or sophisticated experimental setup usu-
ally associated with HPLC methods of analysis. The HPTLC
method uses a minimal volume of solvents and is suitable for
use in quality control laboratories where economy and time
are essential. Reliability was guaranteed by testing various val-
idation parameters of the proposed method and successful
application to laboratory prepared tablets without interference
from commonly encountered dosage form additives. Finally,the proposed method was found accurate and precise; hence,
it can be recommended for the routine analysis of the studied
drugs either in bulk form or in their combined tablet dosage
forms.
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